56F.F EXACT THERAP. AS NK 0004
- Market cap
- EUR 1.12M
- P/E
- -
- P/B
- 0.18x
- ROE
- -283.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 56F.F undervalued?
Graham numberThe Graham number of EXACT THERAP. AS NK 0004 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EXACT THERAP. AS NK 0004 fundamental analysis
No fundamental analysis for EXACT THERAP. AS NK 0004 yet.
EXACT THERAP. AS NK 0004 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EXACT THERAP. AS NK 0004
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform…
Full company profileEXACT THERAP. AS NK 0004 financial statements
EXACT THERAP. AS NK 0004 annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -59.1M | -40.8M | -48.4M | -52.9M | -84.9M |
| EBITDA | - | -38.5M | -46.2M | -49.8M | -83.2M |
| Net Income | -58.6M | -40.1M | -48.3M | -52.3M | -87.0M |
| EPS | -1.95 | -1.34 | -1.51 | -0.83 | -1.37 |
| Balance Sheet | |||||
| Total Assets | 118M | 82.5M | 61.3M | 153M | 67.4M |
| Total Liabilities | 11.9M | 17.4M | 16.3M | 37.7M | 36.7M |
| Shareholders' Equity | 106M | 65.1M | 45.1M | 116M | 30.7M |
| Cash & Short-term Investments | 82.5M | 68.5M | 45.6M | 98.0M | 23.5M |
| Cash Flow | |||||
| Operating Cash Flow | -55.1M | -33.9M | -44.3M | -80.5M | -67.0M |
| Capital Expenditure | 1.63M | 251K | 3.09M | 1.51M | 5.32M |
| Free Cash Flow | -56.7M | -34.1M | -47.4M | -82.1M | -72.3M |
| Ratios | |||||
| ROE | -55.4% | -61.6% | -107.3% | -45.3% | -283.2% |
| ROA | -49.8% | -48.6% | -78.8% | -34.2% | -129.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
EXACT THERAP. AS NK 0004 dividends
EXACT THERAP. AS NK 0004 has not paid dividends in the last 5 fiscal years.
Who owns EXACT THERAP. AS NK 0004
- Insiders 62.08%
- Institutions 21.11%
- Public & others 16.82%
- Shares outstanding 112M
- Free float 62.7M
EXACT THERAP. AS NK 0004 company profile
- Company name
- EXACT THERAP. AS NK 0004
- Ticker
- 56F.F
- ISIN
- NO0010852213
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- December
- Address
- Østre Aker vei 19, Oslo, Norway, 0581
- Website
- exact-tx.com
About EXACT THERAP. AS NK 0004
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform is under Phase 2 clinical trial for the treatment of pancreatic disease; Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. It has a collaboration with GE Healthcare. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.
EXACT THERAP. AS NK 0004 management
8- Dr. Per Edvard Walday Ph.D.Chief Executive Officer · born 1960
- Dr. Svein KvåleCo-Founder & COO
- Mr. John M. EdminsonChief Financial Officer
- Dr. Masha Paule Nathalie Legris Stromme DPHILDirector
- Dr. Amir Snapir M.D., Ph.D.Chief Medical Officer · born 1961
- Mr. Caspar FoghsgaardChief Business Officer
- Dr. Per Christian SontumFounder
- Mr. Ragnar BendicksenVice President of Technology